Overall verdict
Sell
3.1/10
1-year performance
+581.55%
Score breakdown
Up 581.5% over 1 year, 100% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 0.0/10.
23 analysts, target -0.4% vs the price.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine ; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines ; enteric viruses include norovirus ;
public health vaccines consist of Zika, Nipah, and Mpox vaccines ; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc ;
Vertex Pharmaceuticals Incorporated ; Vertex Pharmaceuticals (Europe) Limited ; immatics N.V. ; Defense Advanced Research Projects Agency ; Biomedical Advanced Research and Development Authority ; Institute for Life Changing Medicines ; The Bill & Melinda Gates Foundation ; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Stéphane Bancel
Founded
2010
Employees
4 700
Revenue / employee
413 617 USD
Next earnings
November 5, 2026 (estimated)
Institutional holders
- FMR LLC14.06%
- BlackRock, Inc.8.30%
- VANGUARD CAPITAL MANAGEMENT LLC6.29%
- Capital World Investors6.04%
- BAILLIE GIFFORD & CO4.94%
- STATE STREET CORP4.26%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.22%
- GEODE CAPITAL MANAGEMENT, LLC2.63%
- MORGAN STANLEY2.59%
- Other institutions32.96%
- Rest of the register13.71%
778 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
197.10 USD
52-week low
22.28 USD
1-year performance
581.55%
Rising
Year-to-date performance
510.49%
Rising
Drawdown
0.00%
Near its high
Position in the 52-week range
100% of range
Gross margin 12.6%, the company loses 141.4% of its revenue, ROIC -34.8%, ROE -39.0%.
Net margin
-141.43%
Negative
Sector -15.24%|S&P 12.97%
Gross margin
12.57%
Low
Return on equity (ROE)
-39.00%
Negative
Sector -19.44%|S&P 16.52%
Return on invested capital (ROIC)
-34.83%
Negative
Free cash flow margin (FCF)
-55.83%
Negative
Margin stability
245.9 pts
Very uneven
Revenue to net income
Growth
2.1/10Revenue up 2.1% over 1 year, 19.3% a year over 5.
Revenue (trailing 12 months)
2.2Md USD
Revenue growth (1y)
2.11%
Moderate
Revenue growth (3y)
-89.83%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 29.6x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 23.3x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
P/E vs its own 5-year history
among the 24% lowest valuations
Cheaper than usual
Market cap
72.7Md USD
Financial strength
10.0/10Cash covers 399.2% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-56.96%
Net cash
Cash
5.1Md USD
Cash / market cap
7.07%
Tight
Cash / total debt
399.22%
Net cash
Net debt
-3.9Md USD
Equity
6.8Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 194.82 USD
- MM20152.89
- MM50107.39
- MM20063.40
- RSI 1475.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+26.86%
200-day average slope, 3 months
+58.78%
50-day average slope, 1 month
+50.07%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.88 % per day
Volatility change
-49.84%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -8.38 (20) | -8.40 (18) | 2 101 (20) | -3 236 (8) | -3 313 (16) |
| 2027 | -4.79 (20) | -4.47 (17) | 2 438 (19) | -1 702 (8) | -1 945 (16) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | NTRA | 3.8 | 2.3 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 136.1 % | ||
| 9 | MRNA | 3.1 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | — | -1.7 % | 581.5 % |
